Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Johnson & Johnson (NY:JNJ)

241.26 -5.65 (-2.29%)
Streaming Delayed Price Updated: 10:38 AM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
From Johnson & Johnson
Via Business Wire
News headline image
Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare
Inovalon Unveils New Research, Products, and Solutions to Tackle Healthcare’s Most Complex Challenges 
From Inovalon Holdings, Inc.
Via GlobeNewswire
News headline image
Johnson & Johnson Stock: Setting the Stage for 2025 Highs
Healthcare giant and Dividend Aristocrat Johnson & Johnson is on track to hit new highs in 2025 and may sustain its rally well into 2026. 
Via MarketBeat
News headline image
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Reports Q3 2024 Results
From Johnson & Johnson
Via Business Wire
News headline image
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
Big pharmaceutical firms may lack the potential for rally driven by a breakout drug like small biotechs, but stability and steady growth remain attractive. 
Via MarketBeat
News headline image
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there. 
Via MarketBeat
News headline image
Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Completes Acquisition of V-Wave
From Johnson & Johnson
Via Business Wire
News headline image
Top 3 Risk-Averse Stocks to Add Stability to Your Portfolio
Risk-averse investors can build a stable portfolio by focusing on established companies with consistent dividends and proven track records of success. 
Via MarketBeat
News headline image
3 Undervalued Dividend Stocks Primed for Growth in 2025
These quality dividend stocks look significantly undervalued which gives you an opportunity to pair a high-yield dividend with strong capital appreciation 
Via MarketBeat
News headline image
Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
News headline image
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt
From Beasley Allen Law Firm
Via Business Wire
News headline image
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
From Johnson & Johnson
Via Business Wire
News headline image
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025. 
Via MarketBeat
Topics Economy
News headline image
3 Safe Stocks with Safe Dividends for Your Portfolio
Secure your portfolio with stocks known for their stability and reliable dividend payouts, offering a sense of security during uncertain times. 
Via MarketBeat
Topics Economy
News headline image
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
From Johnson & Johnson
Via Business Wire
News headline image
4 Defensive Stocks to Combat Market Fear, Uncertainty, and Doubt
Shield your investments from market volatility with these four resilient defensive stocks, offering stability and potential growth despite uncertainty. 
Via MarketBeat
Topics Economy
News headline image
Johnson & Johnson to Acquire V-Wave
From Johnson & Johnson
Via Business Wire
News headline image
Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon
These three stocks have a long history of increasing their dividends and are likely to benefit from sector rotation on expectations of lower interest rates 
Via MarketBeat
Topics Artificial Intelligence Economy
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
News headline image
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.